))
Episode 35. Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson
Manage episode 386758190 series 3369804
Kandungan disediakan oleh Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed:
1. Glofitamab for Relapsed/Refractory DLBCL:
https://pubmed.ncbi.nlm.nih.gov/36507690/
2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:
https://pubmed.ncbi.nlm.nih.gov/31451445/
3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:
https://pubmed.ncbi.nlm.nih.gov/36548927/
4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:
https://pubmed.ncbi.nlm.nih.gov/35803286/
5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:
https://pubmed.ncbi.nlm.nih.gov/35366963/
6. Epcoritamab + R2 in high-risk follicular lymphoma:
https://meetings.asco.org/abstracts-presentations/218265
7. Glofitamab in Mantle Cell Lymphoma:
https://ashpublications.org/blood/article/140/Supplement%201/178/489039
47 episod
Kongsi
